Clinical Research

Celldex Therapeutics Inc.

Address
53 Frontage Road Suite 220

Sponsor Overview

assignment
7
sponsored trials
science
2
molecules
location_city
221
research centres
public
17
countries
person_search
261
investigators

Specializations

Chronic urticaria disorders

Celldex Therapeutics Inc. focuses on chronic spontaneous urticaria and chronic inducible urticaria, including cold-induced urticaria and symptomatic dermographism. Its clinical work in this area centers on persistent wheal-and-itch disease burden and provocation-test outcomes.

  • Chronic spontaneous urticaria
  • Chronic inducible urticaria
  • Cold-induced urticaria
  • Symptomatic dermographism

The sponsor’s studies in urticaria span multiple active sites across several countries, reflecting a broad interest in mast cell–driven skin disease and symptom control.

Pruritic inflammatory skin disease

Another key area is prurigo nodularis, a chronic inflammatory dermatologic condition marked by intense itch and nodular skin lesions. The research emphasis is on itch reduction and disease activity in patients with persistent pruritic symptoms.

  • Prurigo nodularis
  • Itch severity
  • Chronic skin inflammation

This area highlights interest in dermatology programs targeting severe itch-associated disease and long-term symptom burden.

Eosinophilic gastrointestinal disease

Celldex Therapeutics Inc. also funds research in eosinophilic esophagitis, with attention to esophageal inflammation and mast cell involvement in the upper gastrointestinal tract. The therapeutic focus extends beyond skin disease into immune-mediated esophageal pathology.

  • Eosinophilic esophagitis
  • Esophageal inflammation
  • Mast cell infiltration

This work places the sponsor within the field of allergic and eosinophilic disorders affecting gastrointestinal function.

Immunology and mast cell biology

Across its clinical portfolio, the sponsor shows a consistent interest in disorders linked to mast cell activation, histamine-mediated symptoms, and immune-driven itching or swelling. These themes connect its dermatology and gastrointestinal programs.

  • Mast cell activation
  • Histamine-mediated symptoms
  • Immune-mediated inflammation

The research landscape is centered on conditions where immune dysregulation produces chronic symptom burden and tissue inflammation.

Sponsored Trials

Trial Name Country Status
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Barzolvolimab in Participants with Cold-Induced Urticaria and Symptomatic DermographismGermany GermanyLithuania LithuaniaPoland PolandSpain SpainRecruiting
A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous UrticariaBelgium BelgiumBulgaria BulgariaCroatia CroatiaCzechia CzechiaDenmark DenmarkFrance FranceGermany GermanyGreece GreeceHungary HungaryItaly ItalyLithuania LithuaniaPoland PolandPortugal PortugalSlovakia SlovakiaSpain SpainThe Netherlands The NetherlandsRecruiting
Efficacy and Safety Evaluation of Barzolvolimab in Adults with Active Eosinophilic Esophagitis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled StudyGermany GermanyItaly ItalyPoland PolandSpain SpainNot Recruiting
Efficacy and Safety Evaluation of Barzolvolimab in Chronic Spontaneous Urticaria Patients Unresponsive to H1 Antihistamines: A Phase 3 Randomized, Double-Blind, Placebo-Controlled TrialBulgaria BulgariaCroatia CroatiaGermany GermanyHungary HungaryItaly ItalyLithuania LithuaniaPoland PolandSlovakia SlovakiaSpain SpainThe Netherlands The NetherlandsNot Recruiting
Efficacy and Safety Evaluation of Barzolvolimab in Prurigo Nodularis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical TrialCroatia CroatiaGermany GermanyPoland PolandSpain SpainNot Recruiting
Efficacy and Safety of Barzolvolimab in Chronic Inducible Urticaria: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging StudyBulgaria BulgariaGermany GermanyHungary HungaryLatvia LatviaLithuania LithuaniaPoland PolandSpain SpainNot Recruiting
Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Symptomatic Despite H1 Antihistamine Treatment: A Phase 3 Randomized, Placebo-Controlled StudyBelgium BelgiumBulgaria BulgariaCzechia CzechiaDenmark DenmarkFrance FranceGermany GermanyGreece GreeceItaly ItalyPoland PolandPortugal PortugalSpain SpainNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
1
Exclusive Molecules
out of 2 total (50% not shared with other sponsors)

This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
60%
Return partnership rate
132 of 221 sites collaborated multiple times

This sponsor has worked with 221 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Skin and Connective Tissue Diseases6 trials
    247 other sponsors
  • 2.
    Digestive System Diseases1 trial
    280 other sponsors

Partnered Research Centres

221 centres
location_city
assignment352
Aarhus University Hospital
Address
Palle Juul-Jensens Boulevard 99, 8200 Aarhus
Learn morearrow_forward
location_city
assignment5
Alerginiu Susirgimu Diagnostikos Ir Gydymo Centras UAB
Address
Seliu G. 64, Vilniaus M. Sav., 08109 Vilnius
Learn morearrow_forward
location_city
assignment28
Alergo Med Osrodek Badan Klinicznych Sp. z o.o.
Address
Ul. Polskiego Czerwonego Krzyza 26, 33-100 Tarnow
Learn morearrow_forward
location_city
assignment42
Alergologia Plus Sp. z o.o.
Address
Ul. Tomasza Drobnika 49, 60-693 Poznan
Learn morearrow_forward
location_city
assignment12
Alersa s.r.o.
Address
Marsala Koneva 985/1, 040 22 Košice
Learn morearrow_forward
location_city
assignment23
Allergo-Derm Bakos Kft.
Address
Baross Utca 20, 5000 Szolnok
Learn morearrow_forward
Page 1 of 37

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Celldex Therapeutics Inc..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.